These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23149919)
1. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Ochoa MC; Fioravanti J; Rodriguez I; Hervas-Stubbs S; Azpilikueta A; Mazzolini G; Gúrpide A; Prieto J; Pardo J; Berraondo P; Melero I Cancer Res; 2013 Jan; 73(1):139-49. PubMed ID: 23149919 [TBL] [Abstract][Full Text] [Related]
2. Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. Ochoa MC; Fioravanti J; Duitman EH; Medina-Echeverz J; Palazon A; Arina A; Dubrot J; Alfaro C; Morales-Kastresana A; Murillo O; Hervas-Stubbs S; Prieto J; Berraondo P; Melero I PLoS One; 2012; 7(12):e52370. PubMed ID: 23285013 [TBL] [Abstract][Full Text] [Related]
3. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. Wu Z; Xu Y J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116 [TBL] [Abstract][Full Text] [Related]
4. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells. Chenoweth MJ; Mian MF; Barra NG; Alain T; Sonenberg N; Bramson J; Lichty BD; Richards CD; Ma A; Ashkar AA J Immunol; 2012 May; 188(9):4149-57. PubMed ID: 22447977 [TBL] [Abstract][Full Text] [Related]
5. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity. Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059 [TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220 [TBL] [Abstract][Full Text] [Related]
7. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515 [TBL] [Abstract][Full Text] [Related]
8. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. Burkett PR; Koka R; Chien M; Chai S; Boone DL; Ma A J Exp Med; 2004 Oct; 200(7):825-34. PubMed ID: 15452177 [TBL] [Abstract][Full Text] [Related]
9. IL-15: targeting CD8+ T cells for immunotherapy. Diab A; Cohen AD; Alpdogan O; Perales MA Cytotherapy; 2005; 7(1):23-35. PubMed ID: 16040381 [TBL] [Abstract][Full Text] [Related]
10. Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation. Perdreau H; Mortier E; Bouchaud G; Solé V; Boublik Y; Plet A; Jacques Y Eur Cytokine Netw; 2010 Dec; 21(4):297-307. PubMed ID: 21078585 [TBL] [Abstract][Full Text] [Related]
11. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives. Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983 [TBL] [Abstract][Full Text] [Related]
12. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927 [TBL] [Abstract][Full Text] [Related]
13. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation. Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115 [TBL] [Abstract][Full Text] [Related]
14. No requirement of trans presentations of IL-15 for human CD8 T cell proliferation. Ota N; Takase M; Uchiyama H; Olsen SK; Kanagawa O J Immunol; 2010 Nov; 185(10):6041-8. PubMed ID: 20926799 [TBL] [Abstract][Full Text] [Related]
15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
16. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. Dubois S; Patel HJ; Zhang M; Waldmann TA; Müller JR J Immunol; 2008 Feb; 180(4):2099-106. PubMed ID: 18250415 [TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733 [TBL] [Abstract][Full Text] [Related]
18. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice. Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637 [TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204 [TBL] [Abstract][Full Text] [Related]
20. IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. Davies E; Reid S; Medina MF; Lichty B; Ashkar AA J Leukoc Biol; 2010 Sep; 88(3):529-36. PubMed ID: 20538758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]